Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

219.72 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period Progress

February 13, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Earnings Scheduled For February 13, 2025 ↗

February 13, 2025

Via Benzinga

Breaking Down Alnylam Pharmaceuticals: 7 Analysts Share Their Views ↗

February 11, 2025

Via Benzinga

Looking Into Alnylam Pharmaceuticals's Recent Short Interest ↗

February 10, 2025

Via Benzinga

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today ↗

January 30, 2025

Via Benzinga

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2024 Financial Results

January 30, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest ↗

January 16, 2025

Via Benzinga

$1000 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today ↗

January 13, 2025

Via Benzinga

What 15 Analyst Ratings Have To Say About Alnylam Pharmaceuticals ↗

January 13, 2025

Via Benzinga

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals

January 12, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

How Is The Market Feeling About Alnylam Pharmaceuticals? ↗

December 24, 2024

Via Benzinga

$100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today ↗

December 09, 2024

Via Benzinga

Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (24 Ratings) ↗

November 04, 2024

Via Benzinga

Alnylam to Webcast Presentation at 43rd Annual J.P. Morgan Healthcare Conference

January 06, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic ↗

January 03, 2025

William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases.

Via Benzinga

Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years ↗

January 03, 2025

Via Benzinga

Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference

November 27, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest ↗

October 31, 2024

Via Benzinga

Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

November 25, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose

November 17, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (24 Ratings) ↗

November 12, 2024

Via Benzinga

This Airbnb Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday ↗

November 12, 2024

Via Benzinga

Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks ↗

November 08, 2024

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers Squibb, Gilead Sciences, and Sanofi, despite challenges for Novo Nordisk and...

Via Benzinga

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

November 04, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity

October 31, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Showcase Latest Data from TTR Franchise and Hypertension Program at American Heart Association Scientific Sessions 2024

October 30, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today ↗

October 23, 2024

Via Benzinga

Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up ↗

October 18, 2024

The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma.

Via Investor's Business Daily

Alnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial Results

October 17, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.